Results 41 to 50 of about 26,737 (201)

Genetic Diversity and Drug Susceptibility Profiles of Multidrug-Resistant Tuberculosis Strains in Southeast China

Infection and Drug Resistance, 2021
Shufang Lin,1 Shuzhen Wei,1 Yong Zhao,1 Zhisong Dai,1 Jian Lin,1 Yu Pang2 1Fujian Provincial Key Laboratory of Zoonosis Research, Fujian Center for Disease Control and Prevention, Fuzhou, People’s Republic of China; 2Department of Bacteriology and ...
Lin S, Wei S, Zhao Y, Dai Z, Lin J, Pang Y   +5 more
doaj  

Characterization of pyrazinamide resistance in consecutive multidrug-resistant mycobacterium tuberculosis isolates in sweden between 2003 and 2015

International Journal of Mycobacteriology, 2017
Background: The first line anti-tuberculosis drug pyrazinamide (PZA) is important when treating PZA susceptible multidrug-resistant tuberculosis (MDR-TB). Several drug resistance surveys have however reported PZA resistance among a significant proportion
Mikael Mansjo, Jim Werngren, Sven Hoffner   +2 more
doaj   +1 more source

Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies

Medicinal Research Reviews, EarlyView.
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva, Alessandra Aiello, Tonino Alonzi, M. Alice Carvalho, Vladimir Finger, Delia Goletti, Sven Hoffner, Yousra Kherabi, Jan Korabecny, Julia Kulczyńska, Agnieszka Kyzioł, Alicia Lacoma, Filomena Martins, Zorica Nanovic, Sepideh Hosseiniporgham, Martina Hrast Rambaher, Leonardo Antonio Sechi, Daria Smalchuk, Grażyna Stochel, Lydia Tabernero, Nancy L. Tateosian, Violeta Valcheva, Anamarija Zega, Mafalda Sarraguça   +23 more
wiley   +1 more source

Designing molecular diagnostics for current tuberculosis drug regimens

Emerging Microbes and Infections, 2023
Diagnostic development must occur in parallel with drug development to ensure the longevity of new treatment compounds. Despite an increasing number of novel and repurposed anti-tuberculosis compounds and regimens, there remains a large number of drugs ...
Sophia B. Georghiou, Margaretha de Vos, Kavindhran Velen, Paolo Miotto, Rebecca E. Colman, Daniela Maria Cirillo, Nazir Ismail, Timothy C. Rodwell, Anita Suresh, Morten Ruhwald   +9 more
doaj   +1 more source

Pyrazinamide induced thrombocytopenia

, 2010
Thrombocytopenia is an uncommon but potentially life-threatening complication of certain antitubercular drugs and is characterized by rapid destruction of platelets whenever offending drug is taken by a susceptible person.
Rajendra Prasad, Kant, Surya, SunishC Anand, Verma, Sanjay Kumar, Gupta, Vaibhav, Anand, Sunish C., SanjayKumar Verma, Surya Kant, Prasad, Rajendra, Vaibhav Gupta   +9 more
core   +3 more sources

Patterns of Drug Resistance, Drug Resistance Conferring Mutations and Genomic DNA Methylation Revealed in Mycobacterium tuberculosis From South Africa

Tropical Medicine &International Health, EarlyView.
ABSTRACT Tuberculosis remains a major public health threat globally, with drug‐resistant strains undermining treatment efficacy. We analyzed 126 Mycobacterium tuberculosis (M. tuberculosis) isolates with diverse drug resistance spectra and selected 35 for whole genome sequencing (WGS) using Illumina NextSeq, SMRT PacBio Onso and SMRT PacBio Revio ...
Unarine Matodzi, Awelani Mutshembele, Eric Mensah, Dillon Muzondiwa, Ndivhuho A. Makhado, Oleg N. Reva   +5 more
wiley   +1 more source

Xanthine oxidase inhibition by allopurinol increases in vitro pyrazinamide-induced hepatotoxicity in HepG2 cells. [PDF]

, 2010
Contains fulltext : 87446.pdf (Publisher’s version ) (Open Access)Despite the important role of pyrazinamide in tuberculosis treatment, little is known about the mechanism of pyrazinamide-induced hepatotoxicity.
Alma Tostmann, Boeree, M.J., Rob E. Aarnoutse, P.N. Richard Richard, Richard, P.N., Martin J. Boeree, Tostmann, A., Aarnoutse, R.E., Wilbert H.M. Peters, Peters, W.H.M.   +9 more
core   +2 more sources

Assessment of Knowledge and Attitudes Toward Potential Drug–Drug and Drug–Food Interactions and Associated Factors Among Health Care Professionals at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: A Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aims The increased likelihood of potential drug–drug interactions (PDDIs) and food–drug interactions (FDIs) is primarily attributed to the increasing use of multiple medications and the practice of taking medicines with food. Healthcare professionals' (HCPs') knowledge and attitudes toward PDDIs and FDIs play a critical role in ...
Melese Legesse Mitku, Yeniewa Kerie Anagaw, Abera Dessie Dagnaw, Derso Teju Geremew, Yeshiwas Ayale Ferede, Tewodros Denekew Haile, Minichil Chanie Worku, Liknaw Workie Limenh, Azmeraw Bekele, Wondim Ayenew   +9 more
wiley   +1 more source

Evolutionary Genetic Analysis of the Pyrazinamidase Gene in Seven Global Populations of Mycobacterium tuberculosis

International Journal of Mycobacteriology
Background: This study aims to identify the signatures of natural selection in the pyrazinamidase (pncA) gene to see if genetic adaptations by Darwinian natural selection have shaped genetic composition of Mycobacterium tuberculosis (Mtb).
Neha Kumari, Nikhat Khan, Aparup Das
doaj   +1 more source

Association between overexpression of efflux pumps genes Rv0191 and Rv3008 and pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis: a multi-center study

BMC Infectious Diseases
Background Pyrazinamide is a drug that helps shorten the duration of tuberculosis treatment. Mutations in the pncA are the most common mechanism of pyrazinamide resistance in M. tuberculosis.
Mohammad Hashemzadeh, Sadegh Hamid, Azar Dokht Khosravi, Saman Soleimanpour, Mohammad Savari   +4 more
doaj   +1 more source